

# Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia

J Tarabeux<sup>1,2,3</sup>, O Kebir<sup>2,3</sup>, J Gauthier<sup>1</sup>, FF Hamdan<sup>4</sup>, L Xiong<sup>1</sup>, A Piton<sup>1</sup>, D Spiegelman<sup>1</sup>, É Henrion<sup>1</sup>, B Millet<sup>2</sup>, S2D team<sup>1,5</sup>, F Fathalli<sup>6</sup>, R Joobar<sup>6</sup>, JL Rapoport<sup>7</sup>, LE DeLisi<sup>8</sup>, É Fombonne<sup>9</sup>, L Mottron<sup>10</sup>, N Forget-Dubois<sup>11</sup>, M Boivin<sup>11,12</sup>, JL Michaud<sup>4</sup>, P Drapeau<sup>5</sup>, RG Lafrenière<sup>1</sup>, GA Rouleau<sup>1,13</sup> and M-O Krebs<sup>2,3,13</sup>

Pharmacological, genetic and expression studies implicate N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia (SCZ). Similarly, several lines of evidence suggest that autism spectrum disorders (ASD) could be due to an imbalance between excitatory and inhibitory neurotransmission. As part of a project aimed at exploring rare and/or *de novo* mutations in neurodevelopmental disorders, we have sequenced the seven genes encoding for NMDA receptor subunits (NMDARs) in a large cohort of individuals affected with SCZ or ASD ( $n = 429$  and  $428$ , respectively), parents of these subjects and controls ( $n = 568$ ). Here, we identified two *de novo* mutations in patients with sporadic SCZ in *GRIN2A* and one *de novo* mutation in *GRIN2B* in a patient with ASD. Truncating mutations in *GRIN2C*, *GRIN3A* and *GRIN3B* were identified in both subjects and controls, but no truncating mutations were found in the *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* genes, both in patients and controls, suggesting that these subunits are critical for neurodevelopment. The present results support the hypothesis that rare *de novo* mutations in *GRIN2A* or *GRIN2B* can be associated with cases of sporadic SCZ or ASD, just as it has recently been described for the related neurodevelopmental disease intellectual disability. The influence of genetic variants appears different, depending on NMDAR subunits. Functional compensation could occur to counteract the loss of one allele in *GRIN2C* and *GRIN3* family genes, whereas *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* appear instrumental to normal brain development and function.

*Translational Psychiatry* (2011) 1, e55; doi:10.1038/tp.2011.52; published online 15 November 2011

## Introduction

Glutamate is the major excitatory neurotransmitter of the central nervous system and is implicated in many basic neuronal functions and central nervous system processes, in particular, learning, memory and synaptic plasticity. N-methyl-D-aspartate receptors (NMDAR) are voltage-dependant ionotropic glutamate receptors and are tetramers containing two NR1 subunits in association with two NR2 (A, B, C or D) and/or NR3 (A or B) subunits. Many of the physiological and pharmacological properties of the NMDAR depend on the specific NR2 and NR3 subunits composition.<sup>1</sup> Behavioral tasks that involve NMDAR include associative learning, working memory, behavioral flexibility or attention. Thus, NMDAR signaling could be a point of convergence to explain

characteristic patterns of symptoms and neurocognitive deficits observed in neurodevelopmental disorders.

In schizophrenia (SCZ), dysregulation of brain glutamate transmission through NMDAR has been proposed as an etiological factor. Indeed, NMDAR antagonists (e.g., ketamine, phencyclidine) produce behavioral and cognitive deficits in normal subjects that closely mimic SCZ,<sup>2–4</sup> and patients with anti-NR1 encephalitis display many SCZ-like symptoms and/or loss of memory.<sup>5–7</sup> Mutant mice lacking NR1 subunit in about half of cortical interneurons early in post-natal development exhibit anxiety-like behaviors and working memory deficits, emerging at adolescence.<sup>8</sup> In addition, NMDAR density and NMDAR subunit composition are reported abnormal in post-mortem brains of patients with SCZ.<sup>9–15</sup>

<sup>1</sup>Center of Excellence in Neuroscience of the Université de Montréal (CENUM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), and Department of Medicine, University of Montreal, Montreal, QC, Canada; <sup>2</sup>INSERM Laboratory of Pathophysiology of Psychiatric Diseases, Center of Psychiatry and Neurosciences, U894, Sainte-Anne Hospital, Paris, France; <sup>3</sup>University Paris Descartes, Faculty of Medicine Paris Descartes, Centre d'Evaluation et de Recherche Clinique, Sainte-Anne Hospital, Paris, France; <sup>4</sup>Centre of Excellence in Neuroscience of Université de Montréal (CENUM), Centre de Recherche du CHU Sainte-Justine, Montreal, QC, Canada; <sup>5</sup>Department of Pathology and Cell Biology and Le Groupe de Recherche sur le Système Nerveux Central, Université de Montréal, Pavillon Roger-Gaudry, Montréal, QC, Canada; <sup>6</sup>Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada; <sup>7</sup>Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, USA; <sup>8</sup>Harvard Medical School, The Boston VA Healthcare System, Brockton, MA, USA; <sup>9</sup>Department of Psychiatry, Montreal Children's Hospital, McGill University, Montreal, QC, Canada; <sup>10</sup>Hôpital Rivière-des-Prairies, Centre d'excellence en Trouble envahissants du développement de Université de Montréal (CETEDUM), Montréal, QC, Canada; <sup>11</sup>Research Unit on Children's Psychosocial Maladjustment, Laval University, Quebec City, QC, Canada and <sup>12</sup>Canada Research Chair on Child Social development, Quebec City, QC, Canada

Correspondence: Professor GA Rouleau, CHUM Research Centre, 2099 Alexandre-De-Seve Street, Rm Y-3633, Montreal, QC, Canada H2L 2W5 or Professor M-O Krebs, Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, UMR 894 INSERM- Université Paris Descartes, Faculté de Médecine Paris Descartes, Service Hospitalo Universitaire, Hôpital Sainte-Anne, 7 rue Cabanis, Paris, France 75014.

E-mail: guy.rouleau@umontreal.ca or marie-odile.krebs@inserm.fr

<sup>13</sup>The last co-authors equally contributed to the work.

**Keywords:** autism; mutation; NMDA; schizophrenia

Received 26 September 2011; accepted 5 October 2011

SCZ has been associated with genetic variants in some of the NMDAR subunit (*NMDARs*) genes including *GRIN2A*, *GRIN2B* and *GRIN1*, although contradictory results were reported (see the SCZgene database: <http://www.szgene.org/>).<sup>16</sup> In addition, several genes that have been associated with increased risk for SCZ, including *NRG1-erb4*, *serine racemase*, *DAO*, *G72* or *dysbindin-1*, are implicated in the modulation of NMDAR activity.<sup>17–19</sup> Lastly, the only consistent report from independent genome-wide association studies in SCZ is the association with genetic markers in the major histocompatibility complex region,<sup>20–22</sup> and recent evidence suggests that major histocompatibility complex region is implicated in neuronal plasticity<sup>23</sup> and glutamatergic receptor modulation.<sup>24</sup>

Dysfunction of NMDA signaling has also been implicated in a wide range of neurological or neurodevelopmental disorders such as intellectual disability (ID),<sup>25,26</sup> in which it appears that specific NMDARs may have different roles in synaptic plasticity and excitotoxicity.<sup>27</sup> In autism spectrum disorders (ASD), potentially causative mutations in *NMDARs* genes have been recently reported,<sup>28,29</sup> and a number of ASD animal models were associated with NMDA abnormalities.<sup>30–33</sup> Moreover, disruption in the balance between excitation and inhibition is a commonly proposed disease mechanism for ASD,<sup>34</sup> and an open-label study with memantine, an antagonist of the NMDAR, significantly improved symptoms.<sup>35</sup> Altogether, the literature suggests that NMDAR number and composition have a crucial role in neurodevelopment and cognition.

Recent studies indicate that rare and penetrant *de novo* mutations could account for some cases of SCZ. For examples, rare chromosomal abnormalities are more frequent in SCZ than in controls, especially rare *de novo* copy number variations<sup>22,36,37</sup> similar to what had been reported in other neurodevelopmental disorders such as ASD<sup>38</sup> and ID.<sup>8,39</sup> In addition, recent reports, including ours, issued from the Synapse to Disease Project, support the implication of *de novo* single nucleotide mutations in ID,<sup>25,40–42</sup> ASD<sup>29,41,43</sup> or SCZ.<sup>44–47</sup> Interestingly, among rare *de novo* variants reported associated with SCZ, two affect genes that may be linked to the glutamatergic synapses: *SHANK3*, encoding a scaffolding protein at the excitatory synapse and *KIF17* encoding a synaptic motor protein, involved in the transport of NMDA receptor 2B (NR2B) to the synapse.<sup>48</sup>

As part of the Synapse to Disease Project, in which we screened 600 synaptic genes, we screened all exons of the seven NMDARs in 571 individuals, including 429 patients with SCZ and 142 patients with ASD. We also screened all exons of the NMDARs (except for *GRIN3B* and *GRIN1*) in 283 healthy controls. Further, we screened additional cohort of ASD patients ( $n=286$ ) for *GRIN2B*, *GRIN2C* and *GRIN3B*, and additional cohort of controls from the general population ( $n=285$ ) for *GRIN2C* and *GRIN3A*. For *GRIN1*, we screened only this general population cohort of controls. Finally, we determined transmission of all unique variants, identified in only one individual, by sequencing parents of the carrier (292 SCZ and 404 ASD patients, with 2 parents available for screening).

We here report the identification of *de novo* mutations in patients with SCZ in the *GRIN2A* gene and in a patient with ASD in the *GRIN2B* gene. Also, we report the absence of truncating mutation in the *GRIN1*, *GRIN2A*, *GRIN2B* and

*GRIN2D* genes in patients or controls, whereas we identified truncating mutations in the *GRIN2C*, *GRIN3A* and *GRIN3B* genes in patients and controls.

## Methods

### Subject collection

**SCZ cohort.** Subjects with SCZ were selected from over 1000 families ascertained for genetic studies, for which DNA samples were available. The screened cohort included 429 subjects with SCZ. We selected in priority patients with no family history of psychiatric disorders ( $n=188$  patient) and patients for which both parents were available ( $n=292$  patients with both parents). To ensure accurate diagnoses, all individuals were evaluated by experienced investigators (JR, LD, MOK and RJ) using the Diagnostic Interview for Genetic Studies or the Kiddie Schedule for Affective Disorders and SCZ and multidimensional neurological, psychological, psychiatric and pharmacological assessments in the recruiting centers. Family history for psychiatric disorders was also collected using the Family Interview for Genetic Studies. All Diagnostic Interview for Genetic Studies and Family Interview for Genetic Studies have been reviewed by two or more psychiatrists for a final consensus diagnosis, based on Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R or DSM-IV at each center. For all probands, specific inclusion criteria for the present study were as follows: (1) the selected proband was definitely affected with SCZ only, not schizophreniform psychosis or bipolar disorders with psychosis; (2) in families with multiple affected individuals, we selected the most severe SCZ case with early ( $<18$  years) or childhood onset ( $<12$  years), and/or additional neurodevelopmental problems, such as ID, dyslexia and epilepsy, but not autistic disorder; for the childhood onset SCZ cohort, ID and epilepsy were exclusionary; (3) Family history was well documented. Finally, exclusion criteria included patients with psychotic symptoms mainly caused by alcohol, drug abuse, or other clinical diagnoses including cytogenetic abnormalities. The final panel of the samples of 429 SCZ subjects were recruited from different centers, that is, 1) 28 cases with childhood-onset SCZ and 66 with later onset SCZ from Judith L Rapoport (NIMH, Bethesda, MD, USA). Cases with childhood onset SCZ were recruited in USA nationwide and assessed as previously described.<sup>49</sup> Individuals in this cohort known to carry the Velo-Cardio-Facial Syndrome (VCFS) deletion on chromosome 22q11 were excluded; 2) 38 cases from Marie-Odile Krebs (Paris, France);<sup>50</sup> 3) 84 cases from Lynn E De Lisi;<sup>51</sup> 4) 7 cases of adult onset SCZ selected from each of seven large highly consanguineous pedigrees with  $\geq 10$  affected individuals with SCZ and schizoaffective disorders from Pakistan; 5) 144 cases from Ridha Joober (Montreal, QC, Canada) including 39 cases from Tunisia;<sup>52</sup> and 6) 62 cases from Hungary.<sup>53</sup> The detailed description of recruitment and ascertainment strategy, diagnostic instruments and criteria have been reported by each center in their previous publications.

**ASD cohort.** The final panel of samples included 428 autistic patients (404 with parental DNA of both parents available).

Diagnostic and selection criteria for the ASD subjects are described in detail elsewhere.<sup>54</sup> We screened 142 autistic patients for the seven *NMDAR* genes, and 286 additional cases were screened for variants in *GRIN2B*, *GRIN2C* and *GRIN3B*. Briefly, all subjects were diagnosed using DSM-IV or DSM-III-R criteria, and depending of the recruitment site, Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation Schedule were used. In addition, the Autism Screening Questionnaire was also completed for all subjects. We excluded patients with an estimated mental age < 18 months, a diagnosis of Rett syndrome or childhood disintegrative disorder, and patients with evidence of any psychiatric and neurological conditions including birth anoxia, rubella during pregnancy, fragile-X disorder, encephalitis, phenylketonuria, tuberous sclerosis, Tourette and West syndromes.

**Control cohorts.** Blood samples were obtained from a total of 568 control subjects. The first control series comprised healthy volunteers that were screened and selected using standardized procedures. Only individuals without any neuropsychiatric symptoms or family history of neuropsychiatric problems were included as SCZ-negative controls. These included 283 adult subjects (131 males; 152 females), 225 of whom were of European origin and 58 were non-Europeans (Tunisian). The second group of controls comprised 285 subjects from a general population control group of mainly French Canadian origin, for whom we also had parental DNA (Quebec Newborn Twin Study; 150 males, 135 females).<sup>55</sup> We have systematically sequenced all exons of the seven *NMDAR* genes (except for *GRIN3B* and *GRIN1*) in the cohort of healthy volunteer controls. When rare truncating mutations were identified, we further screened all exons in additional controls from general population (Quebec Newborn Twin Study). For *GRIN1*, we screened only this general population cohort of controls.

**DNA preparation.** Genomic DNA was extracted from blood using Puregene extraction kit (Gentra System, Minneapolis, MN, USA). For certain individuals in whom blood DNA was limiting, we used DNA isolated from a lymphoblastoid cell line derived from the individual for the screen. In all cases, rare mutations were confirmed using blood-derived DNA to rule out variations having arisen during production or growth of the lymphoblastoid cell line.

**Paternity testing.** Paternity, maternity and unique genetic identification of each individual of all families (subject families and controls) was confirmed using 5–14 highly informative unlinked microsatellite markers as described in Gauthier *et al*.<sup>46</sup>

**Gene screening, variation analysis and bioinformatics.** In each proband, we sequenced the coding region and the splice junction of *GRIN1* (chr9: 140,033,609–140,063,207, hg19 assembly), *GRIN2A* (chr16: 9,847,267–10,276,263), *GRIN2B* (chr12: 13,714,410–14,133,022), *GRIN2C* (chr17: 72,838,168–72,856,007), *GRIN2D* (chr19: 48,898,132–48,948,187), *GRIN3A* (chr9: 104,331,635–104,500,862). *GRIN3B* (chr19: 1,000,437–1,009,723) was sequenced only in patients. The detailed descriptions of the samples screened for each *NMDAR* gene are mentioned in Table 1. Primers were designed using the ExonPrimer program (Helmholtz Center Munich, Munich, Germany) from the UCSC genome browser (Supplementary Table 3). PCR products were sequenced at the McGill University and Genome Quebec Innovation Centre in Montreal, QC, Canada (<http://gqinnovationcenter.com>) on a 3730XL DNA Analyzer System (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA). In each case, variations were confirmed by re-amplifying the fragment and resequencing of the samples from the proband and available parents, using reverse and forward primers. PolyPhred (version 6.11), PolySCAN (v.3.0) and Mutation Surveyor (version 3.10; Soft Genetics, State College, PA, USA) were used for mutation detection analysis. The PolyPhen (<http://genetics.bwh.harvard.edu/pph>), SIFT (<http://blocks.fhrc.org/sift/SIFT.html>), Panther (<http://www.pantherdb.org/tools/csnpScoreForm.jsp>) and SNAP (<http://www.roslab.org/services/SNAP/>) programs were used to predict the overall severity of the missense mutations. In all instances, default parameters were used for each program.

## Results

We found three *de novo* mutations in patients with sporadic ASD or SCZ in *GRIN2A* and *GRIN2B* (Table 2). We also identified one truncating mutations in *GRIN2C*, four truncating mutations in *GRIN3A* and recurrent truncating mutations in *GRIN3B*, both in patients and controls (Table 3). By contrast, we found no truncating mutations in patients or in controls in the *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* genes. All three

**Table 1** Genes and samples screened

	Samples			
	SCZ	ASD	Controls QNTS	Controls
<i>GRIN1</i>	429 subjects (292 trios)	142 trios	285 trios	Not analyzed
<i>GRIN2A</i>	429 subjects (292 trios)	142 trios	Not analyzed	283 subjects
<i>GRIN2B</i>	429 subjects (292 trios)	428 subjects (404 trios)	Not analyzed	283 subjects
<i>GRIN2C</i>	429 subjects (292 trios)	428 subjects (404 trios)	285 trios	283 subjects
<i>GRIN2D</i>	429 subjects (292 trios)	142 trios	Not analyzed	283 subjects
<i>GRIN3A</i>	429 subjects (292 trios)	142 trios	285 trios	283 subjects
<i>GRIN3B</i>	429 subjects (292 trios)	428 subjects (404 trios)	Not analyzed	Not analyzed

Abbreviations: ASD, autism spectrum disorders; SCZ, schizophrenia; QNTS, Quebec Newborn Twin Study. Number of trios indicates individuals having parental DNA from both parents available.

Table 2 Details of *de novo* mutations identified in NMDAR subunits

Gene	Sequence change			Samples			In silico prediction for amino acid substitution				
	Variant type	Protein change	Chr position <sup>a</sup>	Chr	Exon	cDNA change	SCZ	ASD	SIFT	Polyphen	SNAP
GRIN2A	Missense	p.A968T	16	9 858 499	14	c.2902G>A	1 (292 trios)	0 (142 trios)	0,15 (tolerated)	0.069 (benign)	Neutral 89%
	Silent	p.T1223T	16	9 857 732	14	c.3669C>T	1 (292 trios)	0 (142 trios)	/	/	/
GRIN2B	Missense	p.L825V	12	13 720 084	12	c.2473T>G	0 (292 trios)	1 (404 trios)	0,18 (tolerated)	1.567 (possibly damaging)	Non neutral 70%

Abbreviations: ASD, autism spectrum disorders; chr, chromosome; NMDAR, N-methyl-D-aspartate receptor subunit; SCZ, schizophrenia. Number of trios indicates individuals having parental DNA from both parents available.

PolyPhen, <http://genetics.bwh.harvard.edu/pph>. SIFT, <http://blocks.fhcrc.org/sift/SIFT.html>. SNAP, <http://www.roslab.org/services/SNAP>.

<sup>a</sup>Positions according to genome build 37.

*de novo* mutations and truncating mutations in *GRIN2C* and *GRIN3* were reported neither in the most recent 1000 genome release nor in hapmap.

Two *de novo* mutations were identified in the *GRIN2A* gene. The first in a patient with SCZ with no familial history of SCZ was a missense (c.2902G>A; p.A968T) located in the intracellular domain of the protein. It was not predicted as having important functional consequence based on *in silico* analysis (SIFT, PolyPhen and SNAP; Table 2); nevertheless, it modified an amino acid that is highly conserved in mammals. The second one was a silent mutation, c.3669C>T identified in another patient with sporadic SCZ, and was not predicted to be damaging by *in silico* analysis. Paternal age was 39 and maternal age was 29 for this patient. These mutations were not found in the remaining 1707 chromosomes that had been sequenced. None of these patients had a mental retardation with 11 and 12 years of education, respectively.

A missense mutation (c.2473T>G; p.L825V) was identified in the *GRIN2B* gene in a patient with ASD that had no family history of neuropsychiatric disorders or ID. The mutation was confirmed by resequencing blood DNA of this patient and his parents. Paternal age was 36 and maternal age was 32 for this patient. This mutation was absent in the remaining 2279 chromosomes and was predicted by *in silico* analysis as relatively damaging, as it occurred in the last transmembrane domain that is highly conserved among species.

We further analyzed the prevalence of truncating mutations in our subjects. We did not identify any truncating mutations in the *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* genes in 854 individuals including 429 patients with SCZ, 142 with ASD and 283 healthy controls (285 controls from general population for *GRIN1*). By contrast, we identified the same truncating nonsense mutation in the *GRIN2C* gene (c.54G>A; p.W18X) in two individuals. This mutation was first identified in an ASD patient, and this variant was transmitted from his normal father, whereas there was history of mild learning disabilities in the mother. We also found this mutation in a control from the general population.

We also identified four truncating mutations in the *GRIN3A* gene. Two of them were indels creating frameshift in the open-reading frame and creating nonsense codon, one in an individual from the population control cohort (c.2349delC; p.P783PfsX23) and one in a healthy control (c.2424\_2425delAA; p.Q808QfsX5). The two other truncating mutations were single-nucleotide variants. The first one (c.1522C>T; p.Q508X) was identified in a patient diagnosed with catatonic SCZ and was inherited from the mother who had clinical characteristics ranging in the SCZ spectrum. The second one (c.679G>T; p.E227X) was observed in a young control from the general population. Finally, we observed frequent (10%) truncating mutations in the *GRIN3B* gene in the same proportion as described elsewhere in the general population.<sup>56</sup>

Overall, we identified 260 exonic variants in the seven sequenced *NMDARs* genes, including 159 variants that were not referenced in the dbSNP database (Build 132; Supplementary Tables 1 and 2). These variants were all confirmed manually by genotyping the proband and in the respective proband's parents, when available, to determine their inheritance. To avoid rare variants that could be linked to



**Table 3** Details of rare truncating mutations in NMDAR subunits

Gene	Sequence change						Samples		
	Variant type	Protein change	Chr	Chr Position <sup>a</sup>	Exon	cDNA change	ASD frequency	SCZ frequency	Controls frequency
<i>GRIN2C</i>	Nonsense	p.W18X	17	72 851 178	1	c.54G > A	1/428	0/429	1/568
<i>GRIN3A</i>	Nonsense	p.E227X	9	104 499 583	1	c.679G > T	0/142	0/429	1/568
	Nonsense	p.Q508X	9	104 433 172	3	c.1522C > T	0/142	1/429	0/568
	Indel	p.P783PfsX23	9	104 432 345	3	c.2349delC	0/142	0/429	1/568
	Indel	p.Q808QfsX6	9	104 390 612_104 390 613	4	c.2424_2425delAA	0/142	0/429	1/568

Abbreviations: ASD, autism spectrum disorders; chr, chromosome; NMDAR, N-methyl-D-aspartate receptor subunit; SCZ, schizophrenia.

<sup>a</sup>Positions according to genome build 37.

ethnic origin, we removed variants coming from patients with non-Caucasian ethnicity. When doing so, we did not observe either accumulation of rare variants in patients compared with controls or accumulation of more damaging variants in patients, based on *in silico* analysis.

## Discussion

Here, we provide the first systematic study of sequence alterations in all *NMDARs* genes in ASD and SCZ, and report several potentially damaging and/or *de novo* mutations. Indeed, we identified potentially damaging *de novo* mutation in *GRIN2A* and *GRIN2B* associated with sporadic cases of SCZ and ASD, respectively, and truncating mutations in *GRIN2C*, *GRIN3A* and *GRIN3B*, whereas neither truncating nor *de novo* mutations were found in *GRIN1* and *GRIN2D*.

Deep sequencing technologies have brought new insight in the genetics of neurodevelopmental disorders including SCZ. Recent reports of the literature have shown that there should be, in average, less than two *de novo* mutations in the coding sequence per individual and less than one *de novo* that would have an effect on amino acid sequence per individual.<sup>44,57,58</sup>

We here report on three *de novo* mutations, two in *GRIN2A* in two patients suffering from SCZ, and one in *GRIN2B* in a patient with autism. The mutation in *GRIN2B* is one of the mutations quoted in a previous paper reporting an overall rate of *de novo* mutation in autism or SCZ.<sup>44</sup> In this former paper that considers the overall rate of *de novo* mutation, based on partial results, the mutation was unfortunately misclassified as being in a patient with SCZ, whereas it is definitely in a patient with ASD. These mutations were not inherited from unaffected parents, and the patients with *de novo* mutation in *GRIN2A* or *GRIN2B* did not have a predisposing or causative mutation in 600 other synaptic genes that have been sequenced, including SCZ-risk genes, such as *DISC1* (data not shown). Hence, it could be hypothesized that these mutations could be associated with the pathogenesis of ASD or SCZ. This is further supported by the observation that the missense mutation in *GRIN2B* is predicted by *in silico* analysis to be relatively damaging and it occurred in the last transmembrane domain that is highly conserved among species. In addition, one of the *de novo* mutations identified in the *GRIN2A* gene, is located in a domain that is highly conserved in mammals and vertebrates, and is known to be the target of post-translational modifications, especially phosphorylation. In particular, it has been recently proposed that abnormalities

in the neuregulin 1-ErbB4 pathway, which has been implicated in SCZ and known to contribute to NMDAR hypofunction, acts through NMDARs phosphorylation by the Src tyrosine kinase.<sup>18,19</sup>

Several studies have already screened for mutations in some *NMDARs* genes in neurodevelopmental diseases. Williams *et al.*<sup>59</sup> screened for mutations in the *GRIN1* and *GRIN2* genes in patients with SCZ, but did not identify any variants that were clearly relevant to the phenotype, with only a single missense variant identified among 368 individuals (including 184 controls). Endeley *et al.*<sup>25</sup> screened for mutations and cytogenetic abnormalities in the *GRIN2A* and *GRIN2B* genes in patients with ID and found rare damaging *de novo* mutations and truncating mutations in these genes, indicating that these mutations can be pathogenic. Recently Hamdan *et al.*<sup>26</sup> screened *GRIN1* in patients with non-syndromic ID and identified a *de novo* missense and one amino acid in-frame insertion that altered the receptor's activity, the control population in this latter paper being the same as the one used in the present report. Lastly, an exome sequencing study published this year, identified several potentially causative *de novo* mutations on patients with ASD, one of them being in *GRIN2B*, within a splice site.<sup>29</sup> As we do not provide direct evidence of a functional effect of these mutations, we cannot definitely conclude on the causal effect of *de novo* mutations identified in *GRIN2A* and *GRIN2B* genes. It should however be emphasized that there were no truncating mutations in at least 854 individuals (including 283 healthy volunteers) in *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D*, supporting the hypothesis of a high selection pressure on these genes.

In addition to *de novo* mutations, we identified truncating mutations in the *GRIN2C*, *GRIN3A* and *GRIN3B* genes in patients, population controls and/or healthy volunteers. The rate of mutations in the *GRIN3B* gene was in the same proportion as described in the general population, with around 10% of the individuals homozygous for truncating mutation.<sup>56</sup> As this relatively high rate of mutation and as *GRIN3B* is mainly expressed in motor neurons, and thus a role in mental disorders as SCZ and ASD is unlikely, the gene was not further explored in controls.<sup>56,60</sup>

The presence of truncating mutations in controls suggests that loss of function of these subunits leads to little or no effect. For the *GRIN2C* subunit, we identified the same truncating mutation in a patient with autism and in a control. Although the global functioning and learning abilities of this

control appear to be in the normal range, his relatively young age at the time of his evaluation precludes from reaching firm conclusions on the effect of this truncating mutation on his future development.

On the other hand, the loss of function in one allele from the *GRIN3* family genes do not appear to have dramatic consequences as truncating mutations were identified in healthy controls, suggesting some functional compensations. NMDAR containing GRIN2 subunits show large differences in their pharmacological and electrophysiological properties, including glutamate affinity, modulation by glycine, sensitivity to  $Mg^{2+}$  and channel kinetics. As they also show a distinct spatial and chronological pattern of expression, it has been suggested that these receptors may have unique roles in brain development.<sup>1</sup> Unlike most NMDAR that contain GRIN2 subunits, which typically require glycine and glutamate for activation, NMDAR that contain both GRIN1 and GRIN3 subunits are activated by glycine alone. When co-expressed with GRIN1 and GRIN2 subunits, GRIN3 subunits can act as negative modulators, reducing single-channel conductance and  $Ca^{2+}$  permeability.<sup>61</sup> Thus, it is not surprising that rare damaging mutations could have differential effects in the GRIN2 and GRIN3 family of NMDARs.

We identified a large number of rare variants that are not in the dbSNP databases. Based on *in silico* analysis, these variants do not appear to be pathogenic on their own. Further, most of them are inherited from unaffected parents and some of them could be linked to the ethnic origin, as they were more frequent in the Tunisian samples. When excluding the mutations found in subjects that were not of European Caucasian origin, we did not observe any accumulation of rare or more damaging variants in patients compared with controls. Nevertheless, we cannot exclude complex gene interaction that could occur with variants in other genes.

In conclusion, our data support the hypothesis that rare *de novo* mutations in *GRIN2A* or *GRIN2B* could account for some cases of sporadic SCZ or autism. They also further support the implication of NMDARs in psychiatric disorders with neurodevelopmental origin. Nevertheless, a distinct pattern is observed between the different NMDARs. Truncating mutations in *GRIN2C* and *GRIN3* were found in patients and controls, whereas no truncating mutations were found in *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D*. This could indicate that *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* families are crucial in normal brain development and function and/or that functional compensation could occur to counteract the loss of one allele in *GRIN2C* and *GRIN3* family genes.

### Conflict of interest

The authors declare no conflict of interest.

**Acknowledgements.** We would like to thank all the families involved in this study. This work was supported by Genome Canada and G enome Qu ebec, and received co-funding from Universit e de Montr eal for the 'Synapse to Disease' (S2D) project, as well as funding from the Canadian Foundation for Innovation. JT receives a scholarship from the Universit e Paris Descartes (joint program Universit e Paris Descartes – Universit e de Montr eal). GAR holds the Canada Research Chair in Genetics of the Nervous System and a Jeanne-et-J.-Louis-Levesque Chair for the Genetics of Brain Diseases. PD holds the Canada Research Chair in Neuroscience.

JLM is a recipient of the Clinical Investigator Award of CIHR (Canadian Institutes of Health Research). The S2D team is composed of the following additional members: Isabelle Bachand, Marjolaine Chicoine, M elanie C ot e, Kathleen Daignault, Anne Desjarlais, Ousmane Diallo, Sylvia Dobrzniecka, Joannie Duguay, Marina Drits, Philippe Jolivet, Liliane Karamera, Fr ed eric Kuku, Karine Lachapelle, Guy Lalibert e, Sandra Laurent, Annie Levert, Meijiang Liao, Claude Marineau, Carlos Marino, Anne Noreau, Huashan Peng, Annie Raymond, Annie Reynolds, Daniel Rochefort, Judith St-Onge, Pascale Thibodeau, Kazuya Tsurudome, Yan Yang, Sophie Leroy, Narjes Bendjemaa, Katia Ossian, M elanie Chayet and Fay al Mouaffak. We would also like to thank Dr Chawki Benkelfat for several helpful discussions. A portion of the schizophrenia cohort was collected through the Collaborative Network for Family Study in Psychiatry ('R eseau d' tude familiale en Psychiatrie', REFAPSY), supported by the Fondation Pierre Deniker. We also acknowledge the efforts of the members of the G enome Qu ebec Innovation Centre Sequencing (Pierre Lepage, S ebastien Brunet and Hao Fan Yam) and Bioinformatic (Louis L etourneau and Louis Dumond Joseph) groups.

1. Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor subtypes at central synapses. *Sci STKE* 2004; **2004**: re16.
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD *et al*. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry* 1994; **51**: 199–214.
3. Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. *Arch Gen Psychiatry* 2002; **59**: 663–664.
4. Amitai N, Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. *Biol Psychiatry* 2010; **68**: 5–16.
5. Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. *Lancet Neurol* 2008; **7**: 1074–1075.
6. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M *et al*. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 2008; **7**: 1091–1098.
7. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* 2011; **10**: 63–74.
8. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y *et al*. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. *Nat Neurosci* 2010; **13**: 76–83.
9. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. *Brain Res Brain Res Rev* 2000; **31**: 288–294.
10. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. *Am J Psychiatry* 2000; **157**: 1141–1149.
11. Ibrahim HM, Hogg Jr AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. *Am J Psychiatry* 2000; **157**: 1811–1823.
12. Watis L, Chen SH, Chua HC, Chong SA, Sim K. Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. *J Neural Transm* 2008; **115**: 493–511.
13. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH *et al*. First *in vivo* evidence of an NMDA receptor deficit in medication-free schizophrenic patients. *Mol Psychiatry* 2006; **11**: 118–119.
14. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmueller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. *Neurosci Lett* 1980; **20**: 379–382.
15. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP *et al*. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. *J Neurosci* 1996; **16**: 19–30.
16. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ *et al*. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. *Nat Genet* 2008; **40**: 827–834.
17. Banerjee A, Macdonald ML, Borgmann-Winter KE, Hahn CG. Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. *Brain Res Bull* 2010; **83**: 132–139.
18. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH *et al*. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. *Nat Med* 2006; **12**: 824–828.
19. Pitcher GM, Kalia LV, Ng D, Goodfellow NM, Yee KT, Lambe EK *et al*. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. *Nat Med* 2011; **17**: 470–478.
20. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I *et al*. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 2009; **460**: 753–757.
21. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D *et al*. Common variants conferring risk of schizophrenia. *Nature* 2009; **460**: 744–747.

22. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF *et al*. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009; **460**: 748–752.
23. Shtatz CJ. MHC class I: an unexpected role in neuronal plasticity. *Neuron* 2009; **64**: 40–45.
24. Fourgeaud L, Davenport CM, Tyler CM, Cheng TT, Spencer MB, Boulanger LM. MHC class I modulates NMDA receptor function and AMPA receptor trafficking. *Proc Natl Acad Sci USA* 2010; **107**: 22278–22283.
25. Endeley S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I *et al*. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat Genet* 2010; **42**: 1021–1026.
26. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K *et al*. Excess of *de novo* deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. *Am J Hum Genet* 2011; **88**: 306–316.
27. Li R, Huang FS, Abbas AK, Wigstrom H. Role of NMDA receptor subtypes in different forms of NMDA-dependent synaptic plasticity. *BMC Neurosci* 2007; **8**: 55.
28. Gai X, Xie HM, Perin JC, Takahashi N, Murphy K, Wenocur AS *et al*. Rare structural variation of synapse and neurotransmission genes in autism. *Mol Psychiatry*; advance online publication, 1 March 2011 [e-pub ahead of print].
29. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S *et al*. Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. *Nat Genet* 2011; **43**: 585–589.
30. Eadie BD, Cushman J, Kannangara TS, Fanselow MS, Christie BR. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. *Hippocampus*, November 2010.
31. Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2 (MeCP2)-null mouse brain. *Neuroscience* 2010; **168**: 624–632.
32. Rinaldi T, Kulangara K, Antoniello K, Markram H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. *Proc Natl Acad Sci USA* 2007; **104**: 13501–13506.
33. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C *et al*. Neuroigin-1 deletion results in impaired spatial memory and increased repetitive behavior. *J Neurosci* 2010; **30**: 2115–2129.
34. Polleux F, Lauder JM. Toward a developmental neurobiology of autism. *Ment Retard Dev Disabil Res Rev* 2004; **10**: 303–317.
35. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. *J Child Neurol* 2007; **22**: 574–579.
36. Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T *et al*. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. *Mol Psychiatry* 2009; **14**: 774–785.
37. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of *de novo* copy number mutations with sporadic schizophrenia. *Nat Genet* 2008; **40**: 880–885.
38. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R *et al*. Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* 2010; **466**: 368–372.
39. Guilmatre A, Dubourg C, Mosca AL, Legallic S, Goldenberg A, Drouin-Garraud V *et al*. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. *Arch Gen Psychiatry* 2009; **66**: 947–956.
40. Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P *et al*. A *de novo* paradigm for mental retardation. *Nat Genet* 2010; **42**: 1109–1112.
41. Hamdan FF, Daoud H, Rocheford D, Piton A, Gauthier J, Langlois M *et al*. *De novo* mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. *Am J Hum Genet* 2010; **87**: 671–678.
42. Hamdan FF, Gauthier J, Spiegelman D, Noreau A, Yang Y, Pellerin S *et al*. Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. *N Engl J Med* 2009; **360**: 599–605.
43. Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N *et al*. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. *Hum Genet* 2011; **130**: 563–573.
44. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR *et al*. Direct Measure of the *De Novo* Mutation Rate in Autism and Schizophrenia Cohorts. *Am J Hum Genet* 2010; **87**: 316–324.
45. Tarabeux J, Champagne N, Brustein E, Hamdan FF, Gauthier J, Lapointe M *et al*. *De Novo* truncating mutation in kinesin 17 associated with schizophrenia. *Biol Psychiatry* 2010; **7**: 649–656.
46. Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, Brustein E *et al*. *De novo* mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. *Proc Natl Acad Sci USA* 2010; **107**: 7863–7868.
47. Knight HM, Pickard BS, Maclean A, Malloy MP, Soares DC, McRae AF *et al*. A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. *Am J Hum Genet* 2009; **85**: 833–846.
48. Setou A, Nakagawa T, Seog DH, Hirokawa N. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. *Science* 2000; **288**: 1796–1802.
49. Rapoport JL, Addington A, Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us? *Curr Psychiatry Rep* 2005; **7**: 81–82.
50. Gourion D, Goldberger C, Olie JP, Loo H, Krebs MO. Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. *Schizophr Res* 2004; **67**: 23–31.
51. DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW *et al*. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2002; **159**: 803–812.
52. Joobar R, Rouleau GA, Lal S, Dixon M, O'Driscoll G, Palmour R *et al*. Neuropsychological impairments in neuroleptic-responder vs nonresponder schizophrenic patients and healthy volunteers. *Schizophr Res* 2002; **53**: 229–238.
53. Fathalli F, Rouleau GA, Xiong L, Tabbane K, Benkelfat C, Deguzman R *et al*. No association between the DRD3 Ser9Gly polymorphism and schizophrenia. *Schizophr Res* 2008; **98**: 98–104.
54. Piton A, Michaud JL, Peng H, Aradhya S, Gauthier J, Mottron L *et al*. Mutations in the calcium-related gene IL1RAPL1 are associated with autism. *Hum Mol Genet* 2008; **17**: 3965–3974.
55. Lemelin JP, Boivin M, Forget-Dubois N, Dionne G, Seguin JR, Brendgen M *et al*. The genetic-environmental etiology of cognitive school readiness and later academic achievement in early childhood. *Child Dev* 2007; **78**: 1855–1869.
56. Niemann S, Landers JE, Churchill MJ, Hosler B, Sapp P, Speed WC *et al*. Motoneuron-specific NR3B gene: no association with ALS and evidence for a common null allele. *Neurology* 2008; **70**: 666–676.
57. Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. *Genetics* 2000; **156**: 297–304.
58. Lynch M. Rate, molecular spectrum, and consequences of human mutation. *Proc Natl Acad Sci USA* 2010; **107**: 961–968.
59. Williams NM, Bowen T, Spurlock G, Norton N, Williams HJ, Hoogendoorn B *et al*. Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. *Mol Psychiatry* 2002; **7**: 508–514.
60. Niemann S, Kanki H, Fukui Y, Takao K, Fukaya M, Hynynen MN *et al*. Genetic ablation of NMDA receptor subunit NR3B in mouse reveals motoneuronal and nonmotoneuronal phenotypes. *Eur J Neurosci* 2007; **26**: 1407–1420.
61. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE *et al*. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. *Nature* 1998; **393**: 377–381.



**Translational Psychiatry** is an open-access journal published by **Nature Publishing Group**. This work is licensed under the **Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License**. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on the Translational Psychiatry website (<http://www.nature.com/tp>)